ArticleJournal of transplantation2026
Immunological Dynamics and Outcomes of ABO-Incompatible Kidney Transplants: Insights From a 5+-Year Follow-Up at a Transplant-Heavy Tertiary Center in Saudi Arabia.
Article in Journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: ABO-incompatible (ABOi) kidney transplantation is an essential strategy to expand the donor pool for patients with end-stage kidney disease (ESKD). However, it poses significant immunological challenges because of the risk of graft rejection. In Saudi Arabia, where ABOi transplants are limited, there is a paucity of long-term locoregional data on the impact of immunological factors on graft outcomes. This study evaluated ABOi transplant outcomes in patients with more than 5 years of follow-up, with a primary focus on immunological factors and their role in graft survival and rejection. Methods: We analyzed data from 24 adult patients who underwent ABOi kidney transplantation between October 31, 2015, and December 30, 2019, with follow-up until December 31, 2024. Key immunological factors assessed included donor-recipient blood group mismatch, human leukocyte antigen (HLA) mismatches, preformed donor-specific antibodies (DSAs) and non-DSA anti-HLA antibodies, flow cross-match results, and anti-ABO titers before and after transplantation. Posttransplant infections were also evaluated for their potential immunological impact. The desensitization protocol comprised rituximab, plasma exchange, and intravenous immunoglobulin (IVIg), with pretransplant anti-ABO titers required to be ≤ 8. Exclusion criteria included pediatric ABOi kidney transplants and patients experiencing major vascular or surgical complications necessitating re-exploration within 7 days posttransplant. Immunosuppressive therapy included methylprednisolone and ATG induction, with prednisolone, tacrolimus, and mycophenolate mofetil for maintenance. The studied outcomes were graft survival, rejection episodes, graft failure, and all-cause mortality. Results: Over a mean follow-up of 68 ± 12.6 months, graft survival was 91.7% ( Conclusion: ABOi kidney transplantation demonstrates excellent long-term outcomes; however, immunological factors play a pivotal role in determining the risk of rejection. Careful patient selection is warranted, as even seemingly minor immunological factors can provoke graft rejection in the context of ABO incompatibility. Posttransplant infections were not significantly associated with graft dysfunction or rejection. A small sample size allows us to report these findings; however, to review their significance, a larger cohort of patients, incorporating protocol biopsies, in a prospective multicenter study is needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.